Mary Jo Lechowicz, MD, discussed how pre-transplant depth of response informs the choice between autologous and allogeneic HSCT in T-cell lymphoma.
|Slideshows|November 7, 2014
The Surgeon General vs the Marlboro Man: Who Really Won?
Author(s)Alan Blum, MD
The images in this slide set are from an exhibition curated by Alan Blum, MD, at the University of Alabama Gorgas Library (November to December 2013) to commemorate the 50th anniversary of the Surgeon General’s Report on Smoking and Health, released on January 11, 1964 by Dr. Luther Terry.
Advertisement
Advertisement
Related to this article
Jasmine Zain, MD, described the molecular workup to determine whether a secondary malignancy after CAR T-cell therapy reflects direct insertional mutagenesis.
SOHO 2026 sessions covered chemoimmunotherapy in frontline DLBCL, treatment selection via molecular classifiers, and bispecific antibodies for unfit patients.
The FDA cleared the Triton 1 robotic endoscopy system for diagnostic and therapeutic procedures such as colorectal cancer screening and lesion removal.
ASTRO’s first standalone clinical practice guideline for bladder cancer recommends trimodal therapy vs radical cystectomy for select muscle-invasive disease cases.
Investigators are evaluating cesalatamig among patients with advanced cancer in the international phase 1/2 BiPAVE-001 trial.
The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.
Based on updated data from the TRUST-1 trial, a sNDA for taletrectinib has been approved by the FDA for patients with TKI-naive ROS1+ NSCLC.
Advertisement
Advertisement
Trending on CancerNetwork
1
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
2
FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC
3
SOHO 2026: Key Updates Across the Multiple Myeloma Continuum
4
PALOMA-2 Shows Improved Survival vs Historical IV Amivantamab Data
5